Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lung Neoplasms 1

Interventions

Cisplatin 16Cetuximab 16Radiotherapy, Intensity-Modulated 11Radiotherapy 7Docetaxel 7Fluorouracil 5Erlotinib Hydrochloride 5Everolimus 4Carboplatin 4Sorafenib 3Radiation 3Paclitaxel 3Fluorodeoxyglucose F18 3Chemotherapy, Adjuvant 3Biopsy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Ultrasonography 2Taxes 2Sirolimus 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Platinum 2Photochemotherapy 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Gene Expression Profiling 2Drug Therapy 2Cryosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tongue Neoplasms × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡